Comparison of Custodiol-N solution with Custodiol solution in kidney transplantatio
- Conditions
- kidney preservation by Custodiol-N or Custodiol solution before living related kidney transplantationMedDRA version: 17.1 Level: LLT Classification code 10023438 Term: Kidney transplant System Organ Class: 100000004865Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
- Registration Number
- EUCTR2013-005503-13-DE
- Lead Sponsor
- Essen University Hospital, University of Essen, Klinik für Allgemein-, Viszeral- und Transplantationschirugie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 72
1.all indications for kidney transplantation as defined by local transplant law (TPG, Abs. 4, § 10)
2.living donors should fulfil the criteria for living organ donation in accord-ance to local transplant law (TPG, Abs. 3, § 8)
3.recipients awaiting their first transplant
4.recipients = 18 years
5.recipient’s signed informed consent before the transplantation of data use and protection
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 72
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1. any contraindication for performance of a kidney transplantation
as defined by local transplant law (TPG, Abs. 4, § 10)
2. donors or recipients participating in another study involving
compound/interventions aimed at the reduction of preservation
and/or ischemia/reperfusion injury
3. deceased donor kidney transplantation
4. pregnant or lactating recipient patients
5. female recipients of child-bearing potential who are not using
a highly effective contraception method with a pearl-index <1
6. multiorgan transplantation
7. double kidney transplantation
8. perfusion of the kidney by machine perfusion
9. repeated kidney transplantation
10. Panel reactive antibodies > 85%
11. ABO incompatible kidney transplantation
12. Known hypersensitivity/anaphylaxis against iron chelators
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method